Xlife Sciences AG: Transaction with Baliopharm AG
Search jobs
Xlife Sciences AG / Key word(s): Contract
Xlife Sciences AG: Transaction with Baliopharm AG
08-Jan-2021 / 06:47 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
Xlife Sciences AG: Transaction with Baliopharm AG
License Deal of 300 million euros successfully completed
Xlife Sciences AG has reached a licensing agreement with the biotech firm Baliopharm AG, located in Basel. According to the agreement, Xlife Sciences AG will receive 10% of future income from license fees of Baliopharm AG. The Basel-based company is a leader in innovative antibody therapies for the treatment of acute and chronic inflammatory diseases.